Core Insights - The "Qihang·2025 Financial Summit" was successfully held in Beijing, focusing on the theme "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from various sectors [1] - The "Jinzhi Award" was announced, with Xiansheng Pharmaceutical winning the "Resilient Development of Listed Companies" award, highlighting its strong performance and commitment to sustainable growth [1][3] Group 1: Award and Evaluation - The "Jinzhi Award" aims to set benchmarks for high-quality development, guiding listed companies to focus on core businesses, continuous innovation, and social responsibility [3] - The evaluation process involved a quantitative analysis model based on financial data and public information, covering over 8,000 companies in A-shares, Hong Kong stocks, and Chinese concept stocks, resulting in nearly 200 award-winning companies [3] Group 2: Company Performance - Xiansheng Pharmaceutical demonstrated robust growth, with a total revenue of 3.585 billion yuan, a year-on-year increase of 15.1%, and an adjusted net profit of 651 million yuan, up 21.1%, achieving double-digit growth in both revenue and profit [4] - The company has launched ten innovative drugs, generating 2.776 billion yuan in revenue from these products, a 26% increase year-on-year, accounting for 77.4% of total revenue, showcasing a clear core logic for growth driven by innovation [4] Group 3: Innovation and Globalization - Over the past five years, Xiansheng Pharmaceutical has invested nearly 9 billion yuan in R&D, establishing a global pipeline of over 60 innovative drugs, with two new drugs expected to be approved in 2025 and three self-developed clinical products achieving international licensing [4][5] - The company is accelerating its internationalization, with potential total transaction amounts exceeding 2.9 billion USD from collaborations with major global firms, enhancing its recognition and capabilities in innovation [5] - Future strategies include a focus on differentiated, more effective, and large-scale R&D, with continued high-intensity investment in innovation and deepening global expansion to contribute to the pharmaceutical industry's upgrade and public health [5]